Repros Therapeutics (RPRX) Earning Somewhat Favorable Media Coverage, Study Shows
Media headlines about Repros Therapeutics (NASDAQ:RPRX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repros Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.1972130217708 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Repros Therapeutics Inc. (NASDAQ:RPRX) Sees Light Trading Volume with 22K Shares Changing Hands – First News 24 (firstnewspaper24.com)
- Healthcare Stock on Buy Line: Repros Therapeutics Inc. (RPRX) – Street Observer (press release) (streetobserver.com)
- Biotech Stocks on Investors’ Radar — Neothetics, Pieris Pharma, and Repros Therapeutics – PR Newswire (press release) (prnewswire.com)
- Repros Therapeutics Inc. (RPRX) Short Interest Update (americanbankingnews.com)
Separately, Laidlaw lowered Repros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, July 21st.
Shares of Repros Therapeutics (RPRX) traded up 1.6875% during midday trading on Monday, reaching $0.3254. 76,891 shares of the company’s stock traded hands. Repros Therapeutics has a 52-week low of $0.26 and a 52-week high of $2.28. The stock has a 50 day moving average of $0.31 and a 200-day moving average of $0.65. The stock’s market cap is $12.24 million.
Repros Therapeutics (NASDAQ:RPRX) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.14. Repros Therapeutics had a negative return on equity of 412.64% and a negative net margin of 56,062.07%. The company had revenue of $0.01 million during the quarter. On average, equities research analysts expect that Repros Therapeutics will post ($1.07) EPS for the current year.
Repros Therapeutics Company Profile
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.